Trial Profile
Open-Label, Exploratory Study to Evaluate the Effects of QR-010 on Nasal Potential Difference in Subjects With CF With the ΔF508 CFTR Mutation
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Eluforsen (Primary)
- Indications Cystic fibrosis
- Focus Proof of concept; Therapeutic Use
- Sponsors ProQR Therapeutics
- 16 Aug 2017 Final results of this study were orally presented at the European Cystic Fibrosis Conference, According to a ProQR Therapeutics media release.
- 15 Jun 2017 According to a ProQR Therapeutics media release, full data from this trial will be highlighted on R&D day 2017.
- 08 Nov 2016 Status changed from recruiting to completed.